ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 19 of 48
Up
JMBS 2018, 3(2): 107–113
https://doi.org/10.26693/jmbs03.02.107
Clinical Medicine

Dynamics of Echocardiogram Indicators in Patients with Climacteric Syndrome on Diabetes Mellitus Type 2 after а Complex Therapy

Pavlovska M., Pavlovskyi S.
Abstract

The combination of climacteric syndrome and type 2 diabetes mellitus (DM) often occurs on the background of non-alcoholic fatty liver disease (NAFLD) and necessitates the detection of type 2 diabetes in menopause and its adequate treatment. Antihomotoxicological drugs are widely used in treatment and medical rehabilitation of women with these problems. The purpose of the study was to compare the efficacy of complex therapy of climacteric syndrome in patients with DM type 2 and NAFLD by analyzing echocardiographic parameters before and after application of integrated treatment programs using physiotherapeutic and antihomotoxicological agents. Materials and Methods. We conducted a survey of 106 patients aged 45-55 with a climacteric syndrome associated with type 2 diabetes. 20 of these patients revealed ultrasound signs of NAFLD. In order to compare the effectiveness of treatment methods, the patients were divided into 3 groups. Echocardiography was used to analyze the adequacy of complex therapy for patients with climacteric disorders associated with type 2 DM. Results and discussion. After analyzing the patients’ NAFLD after two courses of therapy, it was found that there were no significant differences between the groups, but there was a tendency towards a decrease in the MV and SAP in patients who received additional antihomotoxicological therapy. Evaluation of the effectiveness of treatment was also carried out on a set of indicators that includeв a subjective assessment of patients with their condition (improvement, no dynamics, deterioration), and the results of laboratory and functional studies after the second course of treatment. Improvement was manifested in less frequent displays of climacteric syndrome according to International Menopausal Index (IMI), in the positive dynamics of SBP, DBP and MV, indicators of carbohydrate and lipid metabolism, positive dynamics Echocardiography. The group of patients who completed the treatment without positive dynamics included those who did not notice improvement in quality of their life, reduction of climacteric syndrome manifestations according to the IMI, in the laboratory and/or functional examination containing no positive dynamics of indicators, as well as patients who did not notice significant subjective improvement of their condition. To negative results can be also included the lack of positive subjective dynamics in patients who reported an increase in symptoms, deterioration of biochemical and instrumental indicators. When evaluating the overall effectiveness of treatment, we found out that using contrasting baths and ultrasound therapy gave 63% of effectiveness, while antihomotoxicological agents’ application brought 78%. Conclusions. Summarizing the results, it can be concluded that for patients with climacteric syndrome associated with type 2 DM and NAFLD, a complex including antihomotoxicological agents was more effective. This conclusion was confirmed by the dynamics of echocardiographic indices and subjective evaluation of the state of health and the results of laboratory and functional research after the second course of treatment. From a clinical point of view, the results allow to recommend selected complexes for the correction of functional cardiovascular disorders in women with climacteric disorders and disorders of carbohydrate metabolism.

Keywords: climacteric syndrome, type 2 diabetes mellitus antihomotoxicological therapy, complex treatment

Full text: PDF (Ukr) 225K

References
  1. Akker LV, Stefanovskaya OV, Leonova NV, Khamadyanova SU. Sakharnyy diabet i klimaks: sovremennye vozmozhnosti zamestitelnoy gormonalnoy terapii. Med vestnik Bashkortostana. 2008; 3 (5): 21-4. [Russian]
  2. Zeynalova NV, Kurbanov YaZ, Mirzazade VA, Rzaeva RA, Novruzova MS. Risk serdechno-sosudistoy smerti pri sakharnom diabete 2-go tipa. Klinicheskaya meditsina. 2017; 1: 57-9. [Russian]
  3. Kirilyuk ML. Balneoterapiya, gryazelechenie i fizioterapiya sakharnogo diabeta. Klinichna endokrinologiya ta endokrinna khirurgiya. 2010; 1: 68-76. [Russian]
  4. Kyshakevych IT. Pryrodna menopauza u rizni vikovi periody: yakist zhyttya i taktyka likuvalno-profilaktychnykh zakhodiv: avtoref. dis. … doktora med. nauk, Abstr. Dr. Sci. (Med.). Kyiv: Natsionalna medychna akademiya pislyadyplomnoi osvity im PL Shupyka; 2015. 36 s. [Ukrainian]
  5. Korolevskaya LI. Nemedikamentoznaya profilaktika i vosstanovitelnaya korrektsiya pozdnikh oslozhneniy klimaktericheskogo sindroma u zhenshchin. Mezhdunarodnyy endokrinologicheskiy zhurnal. 2011; 2: 102-11. [Russian]
  6. Mineev VN. Menopauzalnyy sindrom – problema vnutrenney meditsiny. Alternativnye podkhody k lecheniyu menopauzalnykh rasstroystv. Novye Sankt-Peterburgskie Vrachebnye Vedomosti. 2005; 2: 49-56. [Russian]
  7. Tiraspolskiy IV. Antigomotoksicheskaya terapiya v praktike akushera-ginekologa. M: Arnebiya, 2001. 288 s. [Russian]
  8. Ammouri AA, Abu Raddaha AH, Natarajan J, D'Souza MS. Perceptions of risk of coronary heart disease among people living with type 2 diabetes mellitus. Int J Nurs Pract. 2018 Feb; 24 (1). https://www.ncbi.nlm.nih.gov/pubmed/29119639. https://doi.org/10.1111/ijn.12610
  9. Arteaga Urzúa E. Menopause and cardiovascular risk. Rev Med Chil. 2016 Nov; 144 (11): 1375-6. https://doi.org/10.4067/S0034-98872016001100001
  10. Blümel JE, Arteaga E. The risks of avoiding hormone replacement therapy during menopause. Rev Med Chil. 2017 Jun; 145 (6): 760-4. https://doi.org/10.4067/s0034-98872017000600760
  11. Caprnda M, Mesarosova D, Ortega PF, Krahulec B, Egom E, Rodrigo L, Kruzliak P, et al. Glycemic variability and vascular complications in patients with type 2 diabetes mellitus. Folia Med (Plovdiv). 2017 Sep 1; 59 (3): 270-8. https://www.ncbi.nlm.nih.gov/pubmed/28976897. https://doi.org/10.1515/folmed-2017-0048
  12. Engelen SE, Van der Graaf Y, Stam-Slob MC, Grobbee DE, Cramer MJ, Kappelle LJ, et al. Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes. Int J Cardiol. 2017 Dec 1; 248: 301-7. https://www.ncbi.nlm.nih.gov/pubmed/28802735 . https://doi.org/10.1016/j.ijcard.2017.07.081
  13. Karvonen-Gutierrez CA, Park SK, Kim C. Diabetes and menopause. Curr Diab Rep. 2016 Apr; 16 (4): 20. https://www.ncbi.nlm.nih.gov/pubmed/26879303. https://doi.org/10.1007/s11892-016-0714-x
  14. Maffi P, Secchi A. The burden of diabetes: emerging data. Dev Ophthalmol. 2017; 60: 1-5. https://www.ncbi.nlm.nih.gov/pubmed/28427059. https://doi.org/10.1159/000459641
  15. Masoudkabir F, Poorhosseini H, Vasheghani-Farahani A, Hakki E, Roayaei P, Kassaian SE. Synergistic effect of hypertension with diabetes mellitus and gender on severity of coronary atherosclerosis: Findings from Tehran Heart Center registry. ARYA Atheroscler. 2015 Nov; 11 (6): 317-22. https://www.ncbi.nlm.nih.gov/pubmed/26862339. https://www.ncbi.nlm.nih.gov/pmc/articles/4738041
  16. Mauvais-Jarvis F. Gender differences in glucose homeostasis and diabetes. Physiol Behav. 2017 Aug 24. pii: S0031-9384(17)30262-7. https://www.ncbi.nlm.nih.gov/pubmed/28843891. https://doi.org/10.1016/j.physbeh.2017.08.016
  17. Mayor S. Type 2 diabetes triples risk of early menopause, study shows. BMJ. 2013 Dec 27; 347: f7676. https://www.ncbi.nlm.nih.gov/pubmed/24374280. https://doi.org/10.1136/bmj.f7676
  18. Modena MG. Hypertension in postmenopausal women: how to approach hypertension in menopause. High Blood Press Cardiovasc Prev. 2014 Sep; 21 (3): 201-4. https://www.ncbi.nlm.nih.gov/pubmed/24852176. https://doi.org/10.1007/s40292-014-0057-0
  19. Muka T, Asllanaj E, Avazverdi N, Jaspers L, Stringa N, Milic J, Ligthart S, et al. Age at natural menopause and risk of type 2 diabetes: a prospective cohort study. Diabetologia. 2017 Oct; 60 (10): 1951-60. https://www.ncbi.nlm.nih.gov/pubmed/28721436. https://doi.org/10.1007/s00125-017-4346-8
  20. Nuzzo A, Rossi R, Modena MG. Hypertension alone or related to the metabolic syndrome in postmenopausal women. Expert Rev Cardiovasc Ther. 2010 Nov; 8 (11): 1541-8. https://www.ncbi.nlm.nih.gov/pubmed/21090929. https://doi.org/10.1586/erc.10.147
  21. Relton C, Weatherley-Jones E. Homeopathy service in a National Health Service community menopause clinic: audit of clinical outcomes. J Br Menopause Soc. 2005 Jun; 11 (2): 72-3. https://www.ncbi.nlm.nih.gov/pubmed/15970019. https://doi.org/10.1258/136218005775544516
  22. Stuenkel CA. Menopause, hormone therapy and diabetes. Climacteric. 2017 Feb; 20 (1): 11-21. https://www.ncbi.nlm.nih.gov/pubmed/28064520. https://doi.org/10.1080/13697137.2016.1267723
  23. Thompson EA. Homeopathy and the menopause. J Br Menopause Soc. 2002 Dec; 8 (4): 151-4. https://www.ncbi.nlm.nih.gov/pubmed/12804324. https://doi.org/10.1258/136218002100321857